Annual Meeting
`Abstract Issue
`
`SLAYBACK EXHIBIT 1005
`
`Page 1 of 4
`
`SLAYBACK EXHIBIT 1005
`
`Page 1 of 4
`
`

`

`Association for Research in Vision and Ophthalmology
`
`Annual Spring Meeting • Sarasota, Florida • April 28-May 3, 1.991
`
`Table of Contents
`
`Inside Front Cover
`
`Inside Front Cover
`
`MAP OF SARASOTA
`TRANSPORfATION DURING THE MEETING
`GENERAL ASSOCIATION INFORMATION
`ii
`1990-91 Board of Trustees
`. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`ARVO Central Office Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`ii
`iii
`Letter from ARVO Secretary-Treasurer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`iv
`General Business Meeting and Awards Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`ARVO Award Recipients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
`Research Grant Awards Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi
`ARVO Honorary Members . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi
`ARVO Travel Fellowships
`. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi
`... /- j[ IL
`GENE~L ~EETING INF~RMATION
`Reg1strat10n and Information Center ........ . . .. ............ . . ..... ·'·d· 0.., f..... .... .....
`vii
`Placement Service .. ... ... ................ . .. .. . .... . .. . .. .. . ..... ./_.1:·-•·r ':-.'.·>, /1/.:':'!•...,.n . .. . . .. vii
`Book Exhibit ..... .... .. . . .. . , .. .. . ... .... . . .. . . .. . ....... .. ....... -... -. ~ .. :: .. , ... :t,/> .. /.' .. a!' v~
`NEI Conference Room .. . .......... .. ........ .. ........... . . . ...... MA ...... .... · .. . ~ :-... , ....... vu
`Future ARVO Meeting Dates and Location . . . . . ... . . ......... .... ... ... R 2 8. 'ltl' . . . . . . . . . vii
`Special Functions During ARVO Week .. .. .. .. ...... ......... .... . .. ... .. .. .... .. J9].. .. .. . vii
`Section Business Meetings . ...... .. ......... . ... ...... ...... . . ..... 'I,,; :; .. . .. . . . .. . . . . . .. . . . . viii
`ARVO Social Functions ........... . . ....... ... . .......... .. . .. .M:, 1 _. .. J!r;.-~· 11 . • ,. . . • • . • • • • . . viii
`' 1'V'Js S370.n
`SCIENTIFIC PROGRAM INFORMATION
`1991 Program Planning Committee .... .... .... . .................. .. . ...... ..... .. .. ~ .. .. . . . .
`ix
`ix
`On-Site Computer Searches
`. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`Continuing Education Credits .. .. . . . . .. . . . .. .. . . .. . . .. .. .. .. . .. .. . . . . . . . . . . . . . .. .. . . .. . . . . .. x
`Presenter Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x
`Special Sunday Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xi
`Scientific Section Session Schedule (new for 1991) .. .. . . .. .. . . .. . .. .. .. .. . . . . . . . . .. . .. . . . . . .. . xii
`Program Abstracts .... . . . . . .. .- ... . . . . . . . . ... , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`677
`Scientific Program-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Insert
`Author Index
`. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1309
`Permuted Keyword Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1341
`
`1
`
`« VIvlJ/)
`
`'-'
`
`l.o~T
`
`This Abstract Issue has been supported through the generosity of Allergan, Inc.
`
`INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (ISSN 0 146-0404) is published thirteen times per year (monthly
`except in March, in which two issues are published) by the Association for Research in Vision and Ophthalmology, Inc. at J. B.
`Lippincott Company, Downsville Pike, Route 3, Box 20-B, Hagerstown, MD 21740. Business offices are located at East Washing(cid:173)
`ton Square, Philadelphia, PA 19105. Printed in the U.S.A. ©Copyright 1991 by the Association for Research in Vision and
`Ophthalmology, Inc. Second class postage paid at Hagerstown, MD, and at additional mailing offices.
`Subscription information. orders or changes of address: (except Japan, India, Nepal, Bangladesh, and Sri Lanka) Downsville Pike,
`Route 3, Box 20-B, Hagerstown, MD 2(740, or call l-800-638-3030; in Maryland, call collect 301-824-7300. In Japan, contact
`USACO Corporation, 13-12, Shimbashi 1-chome, Minato-ku, Tokyo 105, Japan. In India, Nepal, Bangladesh, and Sri Lanka:
`Universal Subscription Agency Pvt. Ltd., 117 /H-1 /294-B, Model Town, Pandu Nagar, Kanpur-208 025, India. If you are an
`ARVO member, call or write the ARV9 office with your change of address: ARVO, 9650 Rockville Pike, Bethesda, MD 20814;
`(301) 571-1844.
`Annual subscription rates: U.S. $118.00 individual, $157.00 institution; all other countries except Japan, India, Nepal, Bangladesh,
`and Sri Lanka, $159.00 individual, $198.00 institution; residents/students, $80.00. Single copies $17.00. Rates for airmail delivery
`available upon request, Subscription rates in Japan: 48,800 yen individual, 57,400 yen institution (includes airmail postage).
`Copies will be replaced without charge if the publisher receives a request within 60 days of the mailing date in the U.S. or within 5
`months in all othet countries.
`Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by the
`Association for Research in Vision and Ophthalmology for libraries and other users registered with the Copyright Clearance Center
`(C$:C) Transactional Reporting Service, provided that the base fee of$00.80 per copy, plus $00.05 per page is paid directly to CCC,
`21 Congress St., Salem, MA 01970.0146-0404/91 $00.80 + $00;05.
`POSTMASTER: Send address changes to Investigative Ophthalmology & Visual Science, Downsville Pike, Route 3, Box 20-B,
`Hagerstown, MD 21740.
`
`i
`
`SLAYBACK EXHIBIT 1005
`
`Page 2 of 4
`
`

`

`General Association Information
`
`1990-1991 ARVO Board of Trustees
`President
`Henry F. Edelhauser, Ph.D.
`
`President-Elect
`Richard N. Lolley, Ph.D.
`
`Vice President-Elect
`Barbara E.K. Klein, M.D., M.P.H.
`
`Vice President-Elect
`Daniel G. Green, Ph.D.
`
`Immediate Past President
`Stephen D. Klyce, Ph.D.
`
`Secretary-1rreasurer
`Harry A. Quigley, M.D.
`
`SEC1riON 1rRUS1rEES
`
`Anatomy & Pathology
`William Richard Green, M.D.
`Biochemistry & Molecular Biology
`Richard N. Lolley, Ph.D.
`
`Clinical Research
`Barbara E. K. Klein, M.D., M.P.H.
`
`Immunology & Microbiology
`Ronald E. Smith, M.D.
`
`Lens-Elect
`Leo T. Chylack, Jr., M.D.
`Physiology & Pharmacology
`Christopher Paterson, Ph.D., D.Sc.
`
`Cornea-Elect
`Richard A. Thoft, M.D.
`
`Electrophysiology
`Daniel G. Green, Ph.D.
`
`Eye Movements-Elect
`David L. Guyton, M.D.
`
`Glaucoma
`David Epstein, M.D.
`
`Retina
`Lee Jampol, M.D.
`
`Retinal CeU Biology
`Joe G. Hollyfield, Ph.D.
`
`Visual Psychophysics
`Ken Nakayama, Ph.D.
`
`Editor-in-Chief, Investigative Ophthalmology &
`Visual Science
`J. Terry Ernest, M.D., Ph.D.
`
`ARVO Central Office Information
`Joanne G. Angle
`Executive Director
`
`Ann M. Diven
`Manager, Conference Programs
`
`Rosemary Brown
`Conference Assistant/ Placement Service Coordinator
`
`Cynthia Budzenski
`Membership Coordinator/Office Manager
`
`Susan Suit
`Membership Assistant
`
`The Abstract Program Book is mailed to all ARVO members and pre-registered non-member participants in
`March. Everyone is expected to bring this book with them to the Meeting as additional copies are limited and
`can only be given out after the third day of the Meeting. Remember that abstracts are referred to by Program
`Number, as opposed to Page Number, in the Author and Permuted Keyword indices.
`
`ii
`
`SLAYBACK EXHIBIT 1005
`
`Page 3 of 4
`
`

`

`Wednesday 8:30-12:00 noon: Gloucoma
`Paper Presentation
`
`Hernando Desoto Hall North & South
`Wednesday 8:30- 12:00 noon
`
`Glaucoma
`Clinical Pharmacology
`
`MODERATORS: David K. Dueker
`DonaldS. Minckler
`
`PGM#
`1570
`1571
`1572
`
`1573
`1574
`
`1575
`1576
`1577
`
`TIME
`8:30
`8:45
`9:00
`
`9:15
`9:30
`
`9:45
`10:00
`10:15
`
`1578
`
`10:30
`
`1579
`
`10:45
`
`1580
`1581
`1582
`
`1583
`
`11:00
`11:15
`11:30
`
`11:45
`
`AUTHORS
`Lin, Hung, Wang, Ho
`Vocci, Robin, Wahl, Sutton
`Walters, Repass, Sargent, Kelley,
`Stoecker, Chen, Harper
`Bengtsson, Heij1, Lanke
`Van Best, Kuppens, Stolwijk, de
`Keizer
`Chopra, Gordon; Kass, Kolker
`McMahon, Laibovitz
`Cyrlin, Wilkerson, Lippa, Esposito,
`Fazio, Deasy, Panebianco, Yablonski,
`Shields
`Kass, Laibovitz, Lippa,
`Higginbotham, Schuman, Deasy,
`Neafus, Epstein, Wilensky
`Nardin, Lewis, Lippa, Keates,
`Coleman, Clineschmidt, Panebianco,
`Quigley, Zimmerman
`Wang, Carnras, Lee, Podos
`Villumsen, A1m
`Carnras, Schumer, Marsk, Lustgarten,
`Serle, Stjemschantz, Bito, Podos
`Southren, Wandel, Gordon, Weinstein
`
`1571-8:45
`
`APRACLONIDINE: AEFORMULATlON AND DROP SIZE ALTERATION
`M;r!<J Vocdt, ~t", ~~lnl~t
`tSi'lal t-lospilal d Ba1ma8 lnl 'The Joins Hoplci1s UrMrsity,
`Baima8, Mayland
`
`as the IUMI'IIalal1% soUicn. liE ooUd clol::nmo---nW1IBi"*1g d:acy.
`
`Owaic~ci apactri:fne «AD rray beSOIIlll\'kelll!tadby~
`d cty rrwth lnl eyes. These rray be cb!e deponda1l. Aalar!Ualbt ooUd Erhr1oe [A)'s
`oomeal -...c:e II1Ci'a aller parliiV16r1, 18<lD1Q the .-I lor lilt1er ca IC&Culliae d
`[A]- ~the sane IIIVilde ll1d cirala1 a lrnca.U IJIIS!IU1I (lOP) lc7.wmg
`Strlliy, a 1811Jctkr111 ctcp siZB Iran 31 ~I kl16 ~I nl(l1t also h:19aoo oaJar - . y.
`We OOI1"1IB8d tine ct11a1111 forrmJallons d [A] (a O.!!!b visca.B sWifon, a O.!!!b vlsccus
`-I'Aih ~ lnl O.!!!b i:cnYao!llanol ()ft1lhalnic-) lnl the wl*:le cithe
`~ lirrTlJalla1 a1 dolwlad wlh aSIII"Idlltf 31 ~I ctcpsfze. We alsoOilllll'l8dthe
`cxnoerUlaf 1%ao1Aal mtheO.!!!b _ " . . , 16 J1i aq,. The eflectathesefarTUI*rs
`on lOP lowamg ll1d on local in~ sysiBriE- e11ec1s 1'88 ~ i129 heallhy ..u
`vokJrJ'-5 In a f)I05j)IICtkl9 doutJie.milllla, ~. randomlz8d six period
`atlOLWMirstudy. Ead!IIICI!ivecf aJ six - . s in a ra1dcm adarwllh a one week
`W8llhcU bet-. periods. Dflmal dala was cx*'ded on day one .m day sewn d each
`fllllod. Maxilun lOP lowat1g eflect al tine hOIIs llWIIIOd fllln 21.9!b :1: 16.8!b to 26.1%
`:1: 12.0*. for al f<lriUBifcrb. AI farnUams 1'88llfiJ"olicdY -.rtlran 1B:ebo (p< .05)
`butnone-..~ ~dfferantfromeacholher. 1heO.!!!b(cid:173)
`fiD(1Jced lass cty IIDAI1, fiiiQJe, ll1d ~ 111111 tho 1% Ofl1lda*h lllilbl, but tho
`not slllll:slkialy s11J1111cant. Hyctoxypropyl methylceflulose proclJced
`Clh8I1C8S -
`1nnSiant bkJrrBd YBion. llMirB was no SlallsUcl!i <iflur8nce In either~ cr lOP
`
`lowemg; how!Mor, the &l'lllilllrO'Qpebe cld ~a bend---eff8ds.
`
`1572-9:00
`
`A PILOT SllJDY OF lliE EFFICACY AND SAFETY OF AGN 190342·LF 0.02%
`AND 0.08% IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE.
`
`Thomas R Wa!lms 1 Box L BepaE$, I JUlia P Sargent.• Elaine p Kelley 2 ..Jad!..E.
`~2 K®nkuan S, CMn2 David G, Haf!l!ir2, Blomod"r::al 6115J131Ch GroiJp, 1 Austin,
`TIC., Allergan, lnc.,21rvine, CA.
`
`AGN 190342·LF is a relatively selective alpha2-adrenoceptor agonist under investigation
`as an ocular hypotensive agent. Structurally similar to clonidine, both compounds
`possess a 2-amino-imidazoline group. Topically administered, AGN 190342-LF lowers
`intraocular pressure (lOP) in normotensive and ocular hypertensive monkeys, rabbits,
`and cats over a dose range of 0.001% to 1%. lOP reduction appears to be produced by a
`decrease in aqueous humor flow, caused by stimulation of al~adrenoceptors localed,
`in part, on ocular sympalhetic nerve endings. In lhis randomized, double-masked, pilot
`study, we evaluated the efl.,cacy and safety of bilateral, twice-daily administration of
`AGN 190342-LF 0.08%, 0.02% or vehicle in 13 patients wfth open-angle glaucoma or
`ocular hypertension. Overall mean reductions in lOP were 6.0 mm Hg (23.9%), 3.4 mm
`Hg (13.8%), and 2.0 mm Hg (7 .2%) for lhe 0.08%, 0.02o/o, and vehicle groups,
`respectively, following lhree days of treatment. Mean decreases in heart rate, and blood
`pressure were not clinically significant. The results of this pilot study indicate lhat AGN
`190342·LF has potenlial in lhe treatment of elevated intraocular pressure.
`
`1570-8:30
`
`1573-9:15
`
`EFFECT Of TOPICAL Itf>Ot£THACIN AND APRACLONJDIN£ H"l'DROCHLORIDE ON INTRAOCULAR
`PRESSURE IN NORMAL SUBJ£CTS
`Pi ~II'K! I.J n, Por•l )ling llnnq. T::Jinq- l:lunq W11.nq • nd h u -CJ\ri lie
`Department of Ophthalmology, Nmtional Taiwan Unhtereity,
`Taipei, TBiwan, ROC
`
`Indomethacin inhibita the ocular hypotensive action of topicnl epinephrine in
`glaucoma patiento. Thia atudy is to oaoeaa whether the intraocular hypotensive
`effect of aproc:lonidine can alae be aHered by the application of topical indomethacin.
`We performed a randomized double-masked crossover study in ten normal volunteers.
`ThO •ubjecta ~re randomly divided into two group11 of Five. They underwent two
`successive study days in two periods separated by one-week washout time. Each subject
`received 0.1~ topical indomethacin four times daily in one eye and placebo in the
`other eye for the two study daye in both perioda. For group 1 l'!ubjecte, one drop of 1~
`opraclonidine woa p!Bced in the eye receiving indomethacin concurrently and placebo in
`the fellow eye et B A. H. on the eecond doy of the first period. In the second period,
`epraclonidine end placebo ~o<ere exchonged for comperieon. Group II subjecta received
`the eame eyedrope but in reverae sequence. Each subject thua sened a11 hia own control.
`We e:a:amined intraocuhr pressure (I.O.P.) of eoc:h subject ifiVIlediately before the
`fint dose at 8 A.H.
`, then 2, 5 and 8 hours later for every etudy duy.
`We found the intraocular hypotensive effect of apraclonidine lfOB not aignificnntly
`(p>0.1) chsnged by the adminietration of topical prostoglandins-inhibitor,
`indomethacin.
`
`Percent lOP Chonge from Baseline
`2 hr
`5 hr
`8 hr
`
`- ---------------------------
`
`Apraclonidine +Placebo:
`Aprac:lonidine + Indomethacin:
`
`27.1±9.4~
`2B.J±8.B~
`
`J7 . 1:t11.~
`J6.4±9.4~
`
`28.9:!:11.1~
`30.1'1"10.1 :=:
`
`These results ouggeet prostaglandins ore not significantly involved in the
`mechanisms by which aprsclonidine decreeaea ocular preeeure in normal subjects.
`
`U.CK OF SUBSENSITIVITY TO TOPICAL TIMOLOL IN OCULAR HYPERTENSION.
`Boo! Beng<sSQn, Andm Hem. and Jan Lanke. Dept of Ophthalmolgy in
`Malmli and Dept of Statistics, University of Lund, Sweden
`
`132 eyes of &2 patlenls were followed up to 66 IIJOnths in o Dllilked. prospcc(cid:173)
`tive,.r.rndomized srudy of potien" with blgh risk ocular hypertension. Po1ients
`w.:re randomly assigned to tm~tmcn t with topiClll timolol or fll:u:obo. lOP w'"'
`monitored ns affit:c hour Lc:nsion turVes every third month. Patients .who de;•eJ.
`oped glau<OlllC orin whom ole4n lOP rose to2: 35 mmHg Ion the ~rudy. Mean
`baseline lOP w tiS 0.6 mm Hg higltc:r in the timolol-m:n«d eyes than in the
`placebo eyes. At three months lOP was 4.3 mm Hg lower in the timolol than in
`the placebo group. This treatment~induced difference between groups showed
`no signs of diminishing over rime in the eyes remaining in the study.
`
`lOP
`
`28
`
`16
`
`(mmHg)::~ 0 ~~)
`0 ~~n)'•liorst case~
`· r~~~)
`,--,t"'~--:•"'4-"s's:-"".t'a:--::o::oo Months
`
`Those eyes which had to leave the study complicate the picture. However, the
`conclusion is not substantially altered even when we assume a worst-case sce(cid:173)
`nario, viz. that all ex.cluded timolol would have had higher lOP than all re(cid:173)
`maining timolol eyes, while placebo eyes were a random sample of all
`excluded placebo eyes (cf. the middle curve in the figure). Thus, in the present
`material there was no evidence of any decrease over time in the pressure(cid:173)
`reducing effect of timolol.
`
`988
`
`SLAYBACK EXHIBIT 1005
`
`Page 4 of 4
`
`